I'll start by pulling the case and the drug label in parallel, then code the events.
{
"case_id": "ICSR-001",
"study_drug": "Tarlatamab",
"drug_class": "DLL3 T-cell engager (BiTE)",
"patient": {
"age": 64,
"sex": "M",
"comorbidities": [
"ES-SCLC, 2nd line",
"former smoker"
],
"concomitant_meds": [
"dexamethasone premedication",
"ondansetron"
]
},
"narrative": "64-year-old man with extensive-stage small cell lung cancer received his first step-up dose of the DLL3 T-cell engager. Approximately 8 hours after dosing he developed fever to 39.2C with rigors and low blood pressure (88/54) requiring IV fluids; this was graded as cytokine release syndrome. On day 2 nursing noted he was confused with a coarse tremor and a drop in his ICE score (neurotoxicity). He was admitted to hospital and treated with tocilizumab and steroids; symptoms resolved over 48 hours. He was re-dosed at the next cycle with premedication and had only mild recurrence. No infection was identified on workup.",
"events": [
"fever with low blood pressure (CRS)",
"confusion with tremor (neurotoxicity)"
]
}{
"drug_class": "DLL3 T-cell engager (BiTE)",
"examples": [
"Tarlatamab"
],
"labeled": [
"Cytokine release syndrome",
"Immune effector cell-associated neurotoxicity syndrome",
"Pyrexia",
"Neutropenia",
"Anaemia",
"Fatigue",
"Hypotension"
],
"boxed_warning": "Cytokine release syndrome and neurologic toxicity including ICANS.",
"note": "CRS and ICANS are expected, very common, on-target effects of T-cell engagers; typically occur within days of the first/step-up doses."
}Now let me code the individual clinical events to MedDRA PTs.
{
"query": "cytokine release syndrome",
"count": 1,
"matches": [
{
"pt": "Cytokine release syndrome",
"soc": "Immune system disorders",
"synonyms": [
"crs",
"cytokine storm",
"infusion cytokine reaction"
]
}
]
}{
"query": "fever",
"count": 2,
"matches": [
{
"pt": "Febrile neutropenia",
"soc": "Blood and lymphatic system disorders",
"synonyms": [
"fever with low white count",
"neutropenic fever"
]
},
{
"pt": "Pyrexia",
"soc": "General disorders and administration site conditions",
"synonyms": [
"fever",
"high temperature",
"febrile",
"raised temperature"
]
}
]
}{
"query": "low blood pressure",
"count": 1,
"matches": [
{
"pt": "Hypotension",
"soc": "Vascular disorders",
"synonyms": [
"low blood pressure",
"low bp"
]
}
]
}{
"query": "rigors",
"count": 0,
"matches": []
}{
"query": "confusion",
"count": 1,
"matches": [
{
"pt": "Immune effector cell-associated neurotoxicity syndrome",
"soc": "Nervous system disorders",
"synonyms": [
"icans",
"neurotoxicity",
"neurologic toxicity",
"confusion with tremor",
"encephalopathy",
"ice score drop"
]
}
]
}{
"query": "tremor",
"count": 1,
"matches": [
{
"pt": "Immune effector cell-associated neurotoxicity syndrome",
"soc": "Nervous system disorders",
"synonyms": [
"icans",
"neurotoxicity",
"neurologic toxicity",
"confusion with tremor",
"encephalopathy",
"ice score drop"
]
}
]
}{
"query": "neurotoxicity",
"count": 1,
"matches": [
{
"pt": "Immune effector cell-associated neurotoxicity syndrome",
"soc": "Nervous system disorders",
"synonyms": [
"icans",
"neurotoxicity",
"neurologic toxicity",
"confusion with tremor",
"encephalopathy",
"ice score drop"
]
}
]
}Let me check one more term for completeness.
{
"query": "chills",
"count": 0,
"matches": []
}Patient: 64 y/o male, ES-SCLC (2nd line), former smoker
Study drug: Tarlatamab (DLL3 T-cell engager / BiTE)
Concomitant: dexamethasone premed, ondansetron
The narrative describes two clinical syndromes, each with a defining MedDRA PT plus component-symptom PTs. Best practice is to code the diagnostic umbrella term when a syndrome is explicitly diagnosed, and capture the component signs as separate PTs where informative.
| Sign / diagnosis | MedDRA PT | SOC | Role |
|---|---|---|---|
| CRS (diagnosis) | Cytokine release syndrome | Immune system disorders | Primary umbrella PT |
| Fever 39.2 °C | Pyrexia | General disorders & admin site conditions | Component sign |
| Hypotension 88/54 | Hypotension | Vascular disorders | Component sign |
| Rigors | (no exact PT returned; would map to Chills / Pyrexia — flag for dictionary verification) | General disorders | Component sign |
Note: I avoided coding the fever as Febrile neutropenia — there is no neutrophil count in the narrative and "no infection was identified," so that PT is not supported by source data.
| Sign / diagnosis | MedDRA PT | SOC | Role |
|---|---|---|---|
| Neurotoxicity / ICE drop | Immune effector cell-associated neurotoxicity syndrome (ICANS) | Nervous system disorders | Primary umbrella PT |
Confusion, tremor and the ICE-score drop all map (per the teaching dictionary synonyms) to the ICANS PT, so they are captured under the single syndrome term rather than splitting.
| Event (PT) | Serious? | Seriousness criterion met |
|---|---|---|
| Cytokine release syndrome | YES | Hospitalization (admitted); also life-threatening physiology (hypotension/rigors requiring IV fluids + tocilizumab) |
| ICANS | YES | Hospitalization; medically important neurologic event requiring intervention |
| Pyrexia / Hypotension (components) | Serious as part of the serious CRS event | Captured under the CRS hospitalization |
Case is SERIOUS — driven by inpatient hospitalization (an E2A seriousness criterion) and the medically-important, intervention-requiring nature of both syndromes.
Drug-class label confirms: CRS and ICANS are labeled, very common, on-target, boxed-warning effects of DLL3 T-cell engagers, typically within days of the first/step-up dose.
Justification:
- Temporal plausibility: onset ~8 h after the first step-up dose — classic window for BiTE-induced CRS.
- Biological mechanism: CRS is an on-target, expected pharmacologic consequence of T-cell engagement (boxed warning).
- Dechallenge: resolved within 48 h with tocilizumab + steroids (a CRS-directed therapy), supporting drug attribution.
- Positive rechallenge: re-dosed next cycle with only mild recurrence — rechallenge reproduced the reaction (with premedication mitigation), a strong causality signal.
- Alternative cause excluded: "no infection identified on workup," reducing sepsis as a confounder.
Justification:
- Temporal plausibility: day-2 onset, immediately following CRS — the canonical CRS→ICANS sequence for T-cell engagers.
- Mechanism: neurologic toxicity/ICANS is a labeled, boxed-warning effect of the class.
- Dechallenge: resolved over 48 h with steroids.
- Alternative causes: no CNS infection/metabolic cause identified; concomitant meds (dexamethasone, ondansetron) are not plausible causes of an ICANS-type encephalopathy.
Serious case (hospitalization). Two events coded: Cytokine release syndrome (Immune system disorders) and Immune effector cell-associated neurotoxicity syndrome (Nervous system disorders), with component PTs Pyrexia and Hypotension. Both events assessed Related (probable) to tarlatamab — labeled boxed-warning on-target reactions, plausible temporality to the step-up dose, positive dechallenge, positive rechallenge for CRS, and exclusion of infection.
Caveats: "Rigors" did not return an exact PT in the teaching dictionary — verify mapping (likely Chills) in the production MedDRA browser. CRS and ICANS should also be grade-staged (ASTCT) at the company level if grading fields are required.
Patient: 64 y/o male, ES-SCLC (2nd line), former smoker
Study drug: Tarlatamab (DLL3 T-cell engager / BiTE)
Concomitant: dexamethasone premed, ondansetron
The narrative describes two clinical syndromes, each with a defining MedDRA PT plus component-symptom PTs. Best practice is to code the diagnostic umbrella term when a syndrome is explicitly diagnosed, and capture the component signs as separate PTs where informative.
| Sign / diagnosis | MedDRA PT | SOC | Role |
|---|---|---|---|
| CRS (diagnosis) | Cytokine release syndrome | Immune system disorders | Primary umbrella PT |
| Fever 39.2 °C | Pyrexia | General disorders & admin site conditions | Component sign |
| Hypotension 88/54 | Hypotension | Vascular disorders | Component sign |
| Rigors | (no exact PT returned; would map to Chills / Pyrexia — flag for dictionary verification) | General disorders | Component sign |
Note: I avoided coding the fever as Febrile neutropenia — there is no neutrophil count in the narrative and "no infection was identified," so that PT is not supported by source data.
| Sign / diagnosis | MedDRA PT | SOC | Role |
|---|---|---|---|
| Neurotoxicity / ICE drop | Immune effector cell-associated neurotoxicity syndrome (ICANS) | Nervous system disorders | Primary umbrella PT |
Confusion, tremor and the ICE-score drop all map (per the teaching dictionary synonyms) to the ICANS PT, so they are captured under the single syndrome term rather than splitting.
| Event (PT) | Serious? | Seriousness criterion met |
|---|---|---|
| Cytokine release syndrome | YES | Hospitalization (admitted); also life-threatening physiology (hypotension/rigors requiring IV fluids + tocilizumab) |
| ICANS | YES | Hospitalization; medically important neurologic event requiring intervention |
| Pyrexia / Hypotension (components) | Serious as part of the serious CRS event | Captured under the CRS hospitalization |
Case is SERIOUS — driven by inpatient hospitalization (an E2A seriousness criterion) and the medically-important, intervention-requiring nature of both syndromes.
Drug-class label confirms: CRS and ICANS are labeled, very common, on-target, boxed-warning effects of DLL3 T-cell engagers, typically within days of the first/step-up dose.
Justification:
- Temporal plausibility: onset ~8 h after the first step-up dose — classic window for BiTE-induced CRS.
- Biological mechanism: CRS is an on-target, expected pharmacologic consequence of T-cell engagement (boxed warning).
- Dechallenge: resolved within 48 h with tocilizumab + steroids (a CRS-directed therapy), supporting drug attribution.
- Positive rechallenge: re-dosed next cycle with only mild recurrence — rechallenge reproduced the reaction (with premedication mitigation), a strong causality signal.
- Alternative cause excluded: "no infection identified on workup," reducing sepsis as a confounder.
Justification:
- Temporal plausibility: day-2 onset, immediately following CRS — the canonical CRS→ICANS sequence for T-cell engagers.
- Mechanism: neurologic toxicity/ICANS is a labeled, boxed-warning effect of the class.
- Dechallenge: resolved over 48 h with steroids.
- Alternative causes: no CNS infection/metabolic cause identified; concomitant meds (dexamethasone, ondansetron) are not plausible causes of an ICANS-type encephalopathy.
Serious case (hospitalization). Two events coded: Cytokine release syndrome (Immune system disorders) and Immune effector cell-associated neurotoxicity syndrome (Nervous system disorders), with component PTs Pyrexia and Hypotension. Both events assessed Related (probable) to tarlatamab — labeled boxed-warning on-target reactions, plausible temporality to the step-up dose, positive dechallenge, positive rechallenge for CRS, and exclusion of infection.
Caveats: "Rigors" did not return an exact PT in the teaching dictionary — verify mapping (likely Chills) in the production MedDRA browser. CRS and ICANS should also be grade-staged (ASTCT) at the company level if grading fields are required.
Deterministic reference key for ICSR-001 (Tarlatamab). Causality categories follow WHO-UMC; where the narrative supports more than one defensible category the rationale says so. A strong analyst recovers all events, the correct PT/SOC from the dictionary, the right seriousness criterion, and well-reasoned causality grounded in temporality, dechallenge/rechallenge, alternative etiology, and the drug label.
| Event (as narrated) | Expected PT | Expected SOC | Seriousness (ICH E2A) | Causality (WHO-UMC) + rationale |
|---|---|---|---|---|
| fever with low blood pressure (CRS) | Cytokine release syndrome | Immune system disorders | Serious — Hospitalization (and medically important) | Probable — Onset hours after the first step-up dose (tight temporal link), CRS is a labeled/boxed on-target effect of T-cell engagers, no infection found (no alternative cause), positive dechallenge with tocilizumab/steroids and only mild recurrence on rechallenge with premedication. Strong case; 'Certain' is defensible if rechallenge is weighted heavily. |
| confusion with tremor (neurotoxicity) | Immune effector cell-associated neurotoxicity syndrome | Nervous system disorders | Serious — Hospitalization (and medically important) | Probable — Onset day 2 after dosing, ICANS-type neurotoxicity is a labeled/boxed class effect, resolved with steroids (positive dechallenge), no metabolic or structural alternative identified. |
| OVERALL CASE | — | — | Serious — Hospitalization / initially life-threatening (CRS with hypotension) | Case-level ICH-E2A determination |